查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1224492

細胞和基因治療製造市場規模、份額和趨勢分析:按治療類型、規模(研發)、模式、流程(載體生產、細胞庫)、地區、市場,2023-2030

Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 217 Pages | 商品交期: 2-10個工作天內

價格

細胞和基因治療製造的市場增長和趨勢

根據 Grandview Research 的一份新報告，到 2030 年，全球細胞和基因療法製造市場預計將達到 471 億美元。 2023 年至 2030 年，該市場的複合年增長率預計為 26.6%，這是由於臨床管道的快速進展和先進療法的監管批准數量增加，這是市場增長的主要促進因素。

政府當局和主要市場參與者的大量投資也在推動細胞和基因療法製造業的增長。 在過去十年中，公司在基因治療方面的投資約為 23 億美元。 包括 CDMO/CMO 和內部製造商在內的主要服務提供商將這些療法視為活躍的投資領域。 例如，2020 年 5 月，Thermo Fisher Scientific 還投資 1.8 億美元，將其病毒載體製造能力提高一倍。 這些參與者正在通過大力投資建設和/或擴大製造能力或與競爭對手建立戰略聯盟來增加他們的市場佔有率。 因此，這些因素有望成為該市場的主要促進因素。

進入臨床試驗並獲得監管機構上市許可的細胞和基因治療藥物的數量每年都在增加。 截至2019年底，已有17個細胞和基因治療產品獲得美國FDA批准上市。 美國 FDA 預計從 2020 年初開始，每年將收到 200 多個基因和細胞治療 IND。 該監管機構還計劃從 2025 年起每年批准多達 20 種產品。 預計政府的這種支持性努力將在不久的將來推動對細胞和基因治療製造服務的需求。

根據 2020 年 3 月發表的一篇文章，2019 年初美國處於管線（III 期試驗）的細胞和基因治療藥物數量為 289 種，但 2020 年初步達到 362 種。 考慮到臨床前管道，這個數字預計會翻倍。 這一數字的增長表明對細胞和基因治療製造服務的強勁需求。 根據美國生物製藥公司的一份報告，基因和細胞療法正處於早期到晚期的臨床開發階段，重點是治療多種疾病，包括神經系統疾病、遺傳疾病和癌症。

細胞和基因療法製造市場報告要點

細胞療法製造業在 2022 年的收入方面佔據了市場主導地位。 越來越多的正在進行的臨床試驗和越來越多的研究導致了該領域的主導地位

2022 年，處於商業化規模前階段的大量候選分子貢獻了商業化前規模製造細分市場的最大收入份額

隨著對基因和細胞治療產品的監管批准越來越多，對這些療法的商業化生產的需求正在迅速增長，從而增加了商業規模製造領域的份額。

由於許多生物製造商利用 CMO 進行高效快速的產品開發，預計合同製造行業在預測期內將實現利潤豐厚的增長。

此外，臨床管線的持續增加也被認為是加速合同製造行業增長的因素之一。

由於基因治療相關研發的進步以及地區政府增加的投資，北美在收入方面佔據了全球市場的主導地位。

預計亞太地區在預測期內將以最快的速度增長。

這是由更快的審批速度、增加的私人和政府投資以及不斷增長的醫療保健需求推動的。

目次

第 1 章調查方法及範圍

  • 調查方法
  • 調查假設
  • 調查方法
  • 資訊採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要資訊
    • 初步調查
    • 初步調查的詳細資訊
  • 資訊或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細資訊
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
  • 市場：CAGR 計算
  • 二級資訊列表
  • 目的

第 2 章執行摘要

  • 競爭環境
  • 細分市場展望
  • 2022 年市場概覽（百萬美元）

第 3 章市場變量、趨勢和範圍

  • 市場細分
  • 母市場血統
  • 輔助市場系統
  • 治療類型滲透率和增長前景圖，2022 年
  • 市場動態
    • 市場促進因素分析
      • 培養細胞和基因治療管線
      • 合作監管機構
      • 政府和私營公司的投資增加
    • 市場抑制因素分析
      • 與製造相關的技術問題
      • 製造成本高
    • 市場機會分析
      • 藥物開發商/製造商在滿足不斷增長的市場需求方面面臨的壓力越來越大
      • 拓展亞太地區和拉丁美洲等潛在市場
    • 市場問題分析
      • 製造能力不足
  • SWOT 分析；按因素（政治和法律、經濟、技術）
  • 波特的五力分析
  • 對主要交易和戰略聯盟的分析
    • 併購
    • 技術合作
    • 許可和合作夥伴關係
  • COVID-19 影響分析
    • 問題分析
    • 機會分析
    • 主要發展和活動

第 4 章關注製造商

  • 製造細胞和基因療法
    • 擴大細胞和基因治療設施
    • 對主要交易和戰略聯盟的分析
    • 併購
    • 技術合作與夥伴關係
    • 產品批准和發布
  • 細胞和基因治療藥物製造的成本分析
    • 產品分析的總成本
    • 原材料
    • 勞動力成本
    • 過程成本
    • 成本模型
    • 廣告模型
    • 日常模型
    • 混合模型
    • 按技術進行商品成本分析
    • 材料
    • 設備
    • 人力資源
    • 設施

第 5 章處理類型的業務分析

  • 細胞和基因療法的製造市場：治療類型的變化分析
  • 製造細胞療法
    • 幹細胞療法
    • 非幹細胞療法
  • 基因療法製造

第 6 章製造規模業務分析

  • 細胞和基因療法製造市場：規模波動分析
  • 預商業/研發規模製造
  • 商業規模製造

第 7 章模式業務分析

  • 細胞和基因療法的製造市場：模態變化分析
  • 合同製造
    • 合同製造細胞和基因治療製造市場，2018-2030 年（百萬美元）（數量、劑量）
  • 內部製造
    • 內部細胞和基因療法的製造市場，2018-2030 年（百萬美元）（數量、劑量）

第 8 章工作流業務分析

  • 細胞和基因療法的製造市場：工作流程變化分析
  • 細胞處理
  • 細胞銀行
  • 流程開發
  • 填充並完成操作
  • 分析和質量測試
  • 原材料測試
  • 載體生產
  • 其他

第 9 章區域業務分析

  • 北美
    • SWOT 分析
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT 分析
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 義大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT 分析
      • 主要區域動態
    • 日本
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 中國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 印度
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 韓國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 泰國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 拉丁美洲
    • SWOT 分析：
    • 主要地區動態
    • 巴西
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 墨西哥
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 中東和非洲 (MEA)
    • SWOT 分析
    • 主要地區動態
    • 南非
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 沙特阿拉伯
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 科威特
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景

第 10 章競爭格局

  • 戰略框架
  • 市場准入分類
  • 公司簡介
    • Thermo Fisher Scientific, Inc.
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Merck Kgaa
      • 公司概況
      • Milliporesigma
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Lonza
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Catalent, Inc.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Takara Bio, Inc.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • F. Hoffmann-La Roche Ltd.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Wuxi Advanced Therapies
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Samsung
      • 公司簡介
      • Samsung Biologics
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Boehringer Ingelheim International Gmbh
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Novartis Ag
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Hitachi Chemical Co., Ltd.（Showa Denko Materials Co Ltd）
      • 公司概況
      • Apceth Biopharma
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Cellular Therapeutics
      • 公司概況
      • 產品基準
    • Miltenyi Biotech
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Bluebird Bio Inc.
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
  • 按主要公司分類：近期發展和影響分析
  • 企業地圖
  • 供應商情況
    • 主要分銷商和渠道合作夥伴列表
    • 2022 年主要參與者的市場份額分析
  • 上市公司
    • 公司市場分析
    • 競爭儀表板分析
  • 私人公司
    • 主要初創企業名單
    • 本地網路地圖
    • 公司市場分析
Product Code: GVR-4-68038-289-1

Cell And Gene Therapy Manufacturing Market Growth & Trends:

The global cell and gene therapy manufacturing market size is expected to reach USD 47.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 26.6% from 2023 to 2030 owing to the exponential progress of the clinical pipeline, coupled with a rising number of regulatory approvals for advanced therapies, which has majorly driven the growth of the market.

Significant investments by government authorities and key market players are other factors fueling the growth of cell and gene therapy manufacturing. Around USD 2.3 billion was invested in gene therapies by companies over the last decade. Major service providers, including CDMOs/CMOs and in-house manufacturers, consider these therapies as an active area of investment. For instance, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. These players are investing significant amounts either in building and/or expanding manufacturing capabilities or forming strategic alliances with competitors to boost their market presence. Thus, these factors are anticipated to act as primary driving factors for this market.

The number of cell and gene therapies entering clinical trials and later gaining marketing authorization from regulatory bodies is increasing every year. By the end of 2019, 17 cell and gene therapy products were approved by the U.S. FDA for commercial use. The U.S. FDA is expecting to receive over 200 gene and cell treatment INDs annually from the beginning of 2020. The regulatory body is also planning to approve up to 20 products per year from 2025. Such supportive government initiatives are expected to increase the demand for cell and gene therapy manufacturing services in the near future.

Following an article published in March 2020, in the U.S., the number of cell and gene therapies in the pipeline (phase III trials) was 289 at the beginning of 2019, which reached 362 in early 2020. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number indicates the high demand for manufacturing services for cell and gene therapies. According to a report by America's Biopharmaceutical Companies, gene and cell therapies range from early to late stages of clinical development with a focus on a wide spectrum of diseases, including neurologic conditions, genetic disorders, and cancer.

Cell And Gene Therapy Manufacturing Market Report Highlights:

  • The cell therapy manufacturing segment dominated the 2022 market in terms of revenue. A growing number of ongoing clinical trials and increasing research in this space has resulted in the segment dominance
  • A high number of candidate molecules in the pre-commercial scale stage has contributed to the largest revenue share for the pre-commercial scale manufacturing market segment in 2022
  • With an increasing number of regulatory approvals for gene and cell therapy products, the demand for commercial production of these therapies is increasing rapidly, thereby increasing the share of the commercial-scale manufacturing segment
  • The contract manufacturing segment is expected to witness lucrative growth during the forecast period, as a substantial number of biomanufacturers are turning to CMOs for efficient and rapid product development
  • Moreover, the constantly growing clinical pipeline is another contributing factor expected to accelerate contract manufacturing segment growth
  • North America dominated the global market in terms of revenue owing to advancements in research and development pertaining to gene therapy and the increasing number of investments by the regional governments
  • The Asia Pacific region is anticipated to grow at the fastest rate throughout the forecast period
  • This can be attributed to the establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs

Table of Content

Chapter 1 Methodology And Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.8 Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2

Chapter 2 Executive Summary

  • 2.1 Competition Milieu
  • 2.2 Segment Outlook
  • 2.3 Market Summary, 2022 (USD Million)

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation
  • 3.2 Parent Market Lineage
  • 3.3 Ancillary Market Lineage
  • 3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2022
  • 3.5 Market Dynamics
    • 3.5.1 Market Drivers Analysis
      • 3.5.1.1 Growing Pipeline Of Cell And Gene Therapy
      • 3.5.1.2 Supportive Regulatory Bodies
      • 3.5.1.3 Increase In Investment By Government And Private Players
    • 3.5.2 Market Restraint Analysis
      • 3.5.2.1 Technological Challenges Associated With Manufacturing
      • 3.5.2.2 High Cost Of Manufacturing
    • 3.5.3 Market Opportunity Analysis
      • 3.5.3.1 Rising Pressure On Drug Developers/Manufacturers To Meet The Growing Market Demand
      • 3.5.3.2 Expansion In Potential Markets Such As Asia Pacific And Latin America
    • 3.5.4 Market Challenge Analysis
      • 3.5.4.1 Lack Of Manufacturing Capacity
  • 3.6 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
  • 3.7 Porter's Five Forces Analysis
  • 3.8 Major Deals And Strategic Alliances Analysis
    • 3.8.1 Mergers And Acquisitions
    • 3.8.2 Technological Collaborations
    • 3.8.3 Licensing And Partnerships
  • 3.9 Covid-19 Impact Analysis
    • 3.9.1 Challenge Analysis
    • 3.9.2 Opportunity Analysis
    • 3.9.3 Key Developments And Activities

Chapter 4 Focus On Manufacturers

  • 4.1 Cell And Gene Therapy Manufacturing
    • 4.1.1 Facility Expansion For Cell And Gene Therapies
    • 4.1.2 Major Deals And Strategic Alliances Analysis
    • 4.1.3 Mergers And Acquisitions
    • 4.1.4 Technological Collaborations And Partnerships
    • 4.1.5 Product Approvals And Launch
  • 4.2 Cost Of Goods Analysis In Cell And Gene Therapy Manufacturing
    • 4.2.1 Overall Cost Of Goods Analysis
    • 4.2.2 Raw Material
    • 4.2.3 Labor Costs
    • 4.2.4 Process Costs
    • 4.2.5 Cost Models
    • 4.2.6 Campaign Model
    • 4.2.7 Day Rate Model
    • 4.2.8 Hybrid Model
    • 4.2.9 Cost Of Goods Analysis, By Technique
    • 4.2.10 Materials
    • 4.2.11 Equipment
    • 4.2.12 Personnel
    • 4.2.13 Facility

Chapter 5 Therapy Type Business Analysis

  • 5.1 Cell and Gene Therapy Manufacturing Market: Therapy Type Movement Analysis
  • 5.2 Cell Therapy Manufacturing
    • 5.2.1 Cell Therapy Manufacturing Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
    • 5.2.2 Stem Cell Therapy
    • 5.2.3 Cell Therapy Manufacturing Market Estimates And Forecast For Stem Cell Therapy, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
    • 5.2.4 Non-Stem Cell Therapy
    • 5.2.5 Cell Therapy Manufacturing Market Estimates And Forecast For Non-Stem Cell Therapy, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
  • 5.3 Gene Therapy Manufacturing
    • 5.3.1 Gene Therapy Manufacturing Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume, Number Of Doses)

Chapter 6 Manufacturing Scale Business Analysis

  • 6.1 Cell And Gene Therapy Manufacturing Market: Scale Movement Analysis
  • 6.2 Precommercial/R&D Scale Manufacturing
    • 6.2.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Precommercial/R&D Scale Manufacturing, 2018 - 2030 (USD Million)
  • 6.3 Commercial-Scale Manufacturing
    • 6.3.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Commercial-Scale Manufacturing, 2018 - 2030 (USD Million)

Chapter 7 Mode Business Analysis

  • 7.1 Cell And Gene Therapy Manufacturing Market: Mode Movement Analysis
  • 7.2 Contract Manufacturing
    • 7.2.1 Cell And Gene Therapy Manufacturing Market For Contract Manufacturing, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
  • 7.3 In-House Manufacturing
    • 7.3.1 Cell And Gene Therapy Manufacturing Market For In-House Manufacturing, 2018 - 2030 (USD Million) (Volume, Number Of Doses)

Chapter 8 Workflow Business Analysis

  • 8.1 Cell And Gene Therapy Manufacturing Market: Workflow Movement Analysis
  • 8.2 Cell Processing
    • 8.2.1 Cell And Gene Therapy Manufacturing Market For Cell Processing, 2018 - 2030 (USD Million)
  • 8.3 Cell Banking
    • 8.3.1 Cell And Gene Therapy Manufacturing Market For Cell Banking, 2018 - 2030 (USD Million)
  • 8.4 Process Development
    • 8.4.1 Cell And Gene Therapy Manufacturing Market For Process Development, 2018 - 2030 (USD Million)
  • 8.5 Fill And Finish Operations
    • 8.5.1 Cell And Gene Therapy Manufacturing Market For Fill And Finish Operations, 2018 - 2030 (USD Million)
  • 8.6 Analytical And Quality Testing
    • 8.6.1 Cell And Gene Therapy Manufacturing Market For Analytical And Quality Testing, 2018 - 2030 (USD Million)
  • 8.7 Raw Material Testing
    • 8.7.1 Cell And Gene Therapy Manufacturing Market For Raw Material Testing, 2018 - 2030 (USD Million)
  • 8.8 Vector Production
    • 8.8.1 Cell And Gene Therapy Manufacturing Market For Vector Production, 2018 - 2030 (USD Million)
  • 8.9 Others
    • 8.9.1 Cell And Gene Therapy Manufacturing Market For Others, 2018 - 2030 (USD Million)

Chapter 9 Regional Business Analysis

  • 9.1 North America
    • 9.1.1 Swot Analysis
      • 9.1.1.1 North America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.1.2 U.S.
      • 9.1.2.1 Key Country Dynamics
      • 9.1.2.2 Target Disease Prevalence
      • 9.1.2.3 Competitive Scenario
      • 9.1.2.4 Regulatory Framework
      • 9.1.2.5 Reimbursement Scenario
      • 9.1.2.6 U.S. Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.1.3 Canada
      • 9.1.3.1 Key Country Dynamics
      • 9.1.3.2 Target Disease Prevalence
      • 9.1.3.3 Competitive Scenario
      • 9.1.3.4 Regulatory Framework
      • 9.1.3.5 Reimbursement Scenario
      • 9.1.3.6 Canada Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2 Europe
    • 9.2.1 Swot Analysis
      • 9.2.1.1 Europe Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 Germany
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 Germany Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3 U.K.
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 UK Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4 France
      • 9.2.4.1 Key Country Dynamics
      • 9.2.4.2 Target Disease Prevalence
      • 9.2.4.3 Competitive Scenario
      • 9.2.4.4 Regulatory Framework
      • 9.2.4.5 Reimbursement Scenario
      • 9.2.4.6 France Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.5 Italy
      • 9.2.5.1 Key Country Dynamics
      • 9.2.5.2 Target Disease Prevalence
      • 9.2.5.3 Competitive Scenario
      • 9.2.5.4 Regulatory Framework
      • 9.2.5.5 Reimbursement Scenario
      • 9.2.5.6 Italy Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.6 Spain
      • 9.2.6.1 Key Country Dynamics
      • 9.2.6.2 Target Disease Prevalence
      • 9.2.6.3 Competitive Scenario
      • 9.2.6.4 Regulatory Framework
      • 9.2.6.5 Reimbursement Scenario
      • 9.2.6.6 Spain Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.7 Denmark
      • 9.2.7.1 Key Country Dynamics
      • 9.2.7.2 Target Disease Prevalence
      • 9.2.7.3 Competitive Scenario
      • 9.2.7.4 Regulatory Framework
      • 9.2.7.5 Reimbursement Scenario
      • 9.2.7.6 Denmark Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.8 Sweden
      • 9.2.8.1 Key Country Dynamics
      • 9.2.8.2 Target Disease Prevalence
      • 9.2.8.3 Competitive Scenario
      • 9.2.8.4 Regulatory Framework
      • 9.2.8.5 Reimbursement Scenario
      • 9.2.8.6 Sweden Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.9 Norway
      • 9.2.9.1 Key Country Dynamics
      • 9.2.9.2 Target Disease Prevalence
      • 9.2.9.3 Competitive Scenario
      • 9.2.9.4 Regulatory Framework
      • 9.2.9.5 Reimbursement Scenario
      • 9.2.9.6 Norway Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3 Asia Pacific
    • 9.3.1 SWOT Analysis
      • 9.3.1.1 Key Region Dynamics
      • 9.3.1.2 Asia Pacific Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Japan
      • 9.3.2.1 Target Disease Prevalence
      • 9.3.2.2 Competitive Scenario
      • 9.3.2.3 Regulatory Framework
      • 9.3.2.4 Reimbursement Scenario
      • 9.3.2.5 Japan Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 China
      • 9.3.3.1 Target Disease Prevalence
      • 9.3.3.2 Competitive Scenario
      • 9.3.3.3 Regulatory Framework
      • 9.3.3.4 Reimbursement Scenario
      • 9.3.3.5 China Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 India
      • 9.3.4.1 Target Disease Prevalence
      • 9.3.4.2 Competitive Scenario
      • 9.3.4.3 Regulatory Framework
      • 9.3.4.4 Reimbursement Scenario
      • 9.3.4.5 India Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5 South Korea
      • 9.3.5.1 Target Disease Prevalence
      • 9.3.5.2 Competitive Scenario
      • 9.3.5.3 Regulatory Framework
      • 9.3.5.4 Reimbursement Scenario
      • 9.3.5.5 South Korea Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6 Australia
      • 9.3.6.1 Target Disease Prevalence
      • 9.3.6.2 Competitive Scenario
      • 9.3.6.3 Regulatory Framework
      • 9.3.6.4 Reimbursement Scenario
      • 9.3.6.5 Australia Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7 Thailand
      • 9.3.7.1 Target Disease Prevalence
      • 9.3.7.2 Competitive Scenario
      • 9.3.7.3 Regulatory Framework
      • 9.3.7.4 Reimbursement Scenario
      • 9.3.7.5 Thailand Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4 Latin America
    • 9.4.1 Swot Analysis:
    • 9.4.2 Key Regional Dynamics
      • 9.4.2.1 Latin America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3 Brazil
      • 9.4.3.1 Target Disease Prevalence
      • 9.4.3.2 Competitive Scenario
      • 9.4.3.3 Regulatory Framework
      • 9.4.3.4 Reimbursement Scenario
      • 9.4.3.5 Brazil Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4 Mexico
      • 9.4.4.1 Target Disease Prevalence
      • 9.4.4.2 Competitive Scenario
      • 9.4.4.3 Regulatory Framework
      • 9.4.4.4 Reimbursement Scenario
      • 9.4.4.5 Mexico Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5 Argentina
      • 9.4.5.1 Target Disease Prevalence
      • 9.4.5.2 Competitive Scenario
      • 9.4.5.3 Regulatory Framework
      • 9.4.5.4 Reimbursement Scenario
      • 9.4.5.5 Argentina Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5 Middle East & Africa (MEA)
    • 9.5.1 Swot Analysis
    • 9.5.2 Key Regional Dynamics
      • 9.5.2.1 Middle East & Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3 South Africa
      • 9.5.3.1 Target Disease Prevalence
      • 9.5.3.2 Competitive Scenario
      • 9.5.3.3 Regulatory Framework
      • 9.5.3.4 Reimbursement Scenario
      • 9.5.3.5 South Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4 Saudi Arabia
      • 9.5.4.1 Target Disease Prevalence
      • 9.5.4.2 Competitive Scenario
      • 9.5.4.3 Regulatory Framework
      • 9.5.4.4 Reimbursement Scenario
      • 9.5.4.5 Saudi Arabia Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.5 UAE
      • 9.5.5.1 Target Disease Prevalence
      • 9.5.5.2 Competitive Scenario
      • 9.5.5.3 Regulatory Framework
      • 9.5.5.4 Reimbursement Scenario
      • 9.5.5.5 UAE Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.6 Kuwait
      • 9.5.6.1 Target Disease Prevalence
      • 9.5.6.2 Competitive Scenario
      • 9.5.6.3 Regulatory Framework
      • 9.5.6.4 Reimbursement Scenario
      • 9.5.6.5 Kuwait Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Strategy Framework
  • 10.2 Market Participation Categorization
  • 10.3 Company Profiles
    • 10.3.1 Thermo Fisher Scientific, Inc.
      • 10.3.1.1 Company Overview
      • 10.3.1.2 Financial Performance
      • 10.3.1.3 Product Benchmarking
      • 10.3.1.4 Strategic Initiatives
    • 10.3.2 Merck Kgaa
      • 10.3.2.1 Company Overview
      • 10.3.2.1.1 Milliporesigma
      • 10.3.2.2 Financial Performance
      • 10.3.2.3 Product Benchmarking
      • 10.3.2.4 Strategic Initiatives
    • 10.3.3 Lonza
      • 10.3.3.1 Company Overview
      • 10.3.3.2 Financial Performace
      • 10.3.3.3 Product Benchmarking
      • 10.3.3.4 Strategic Initiatives
    • 10.3.4 Catalent, Inc.
      • 10.3.4.1 Company Overview
      • 10.3.4.2 Financial Performance
      • 10.3.4.3 Product Benchmarking
      • 10.3.4.4 Strategic Initiatives
    • 10.3.5 Takara Bio, Inc.
      • 10.3.5.1 Company Overview
      • 10.3.5.2 Financial Performance
      • 10.3.5.3 Product Benchmarking
      • 10.3.5.4 Strategic Initiatives
    • 10.3.6 F. Hoffmann-La Roche Ltd.
      • 10.3.6.1 Company Overview
      • 10.3.6.2 Financial Performance
      • 10.3.6.3 Product Benchmarking
      • 10.3.6.4 Strategic Initiatives
    • 10.3.7 Wuxi Advanced Therapies
      • 10.3.7.1 Company Overview
      • 10.3.7.2 Financial Performance
      • 10.3.7.3 Product Benchmarking
      • 10.3.7.4 Strategic Initiatives
    • 10.3.8 Samsung
      • 10.3.8.1 Company Overview
      • 10.3.8.1.1 Samsung Biologics
      • 10.3.8.2 Company Overview
      • 10.3.8.3 Financial Performance
      • 10.3.8.4 Product Benchmarking
      • 10.3.8.5 Strategic Initiatives
    • 10.3.9 Boehringer Ingelheim International Gmbh
      • 10.3.9.1 Company Overview
      • 10.3.9.2 Financial Performance
      • 10.3.9.3 Product Benchmarking
      • 10.3.9.4 Strategic Initiatives
    • 10.3.10 Novartis Ag
      • 10.3.10.1 Company Overview
      • 10.3.10.2 Financial Performance
      • 10.3.10.3 Product Benchmarking
      • 10.3.10.4 Strategic Initiatives
    • 10.3.11 Hitachi Chemical Co., Ltd. (Showa Denko Materials Co Ltd)
      • 10.3.10.1 Company Overview
      • 10.3.10.1.1 Apceth Biopharma
      • 10.3.10.2 Company Overview
      • 10.3.10.3 Financial Performance
      • 10.3.10.4 Product Benchmarking
      • 10.3.10.5 Strategic Initiatives
    • 10.3.12 Cellular Therapeutics
      • 10.3.12.1 Company Overview
      • 10.3.12.2 Product Benchmarking
    • 10.3.13 Miltenyi Biotech
      • 10.3.13.1 Company Overview
      • 10.3.13.2 Financial Performance
      • 10.3.13.3 Product Benchmarking
      • 10.3.13.4 Strategic Initiatives
    • 10.3.14 Bluebird Bio Inc.
      • 10.3.14.1 Company Overview
      • 10.3.14.2 Financial Performance
      • 10.3.14.3 Product Benchmarking
      • 10.3.14.4 Strategic Initiatives
  • 10.4 Recent Developments And Impact Analysis By Key Market Participants
  • 10.5 Company Mapping
  • 10.6 Vendor Landscape
    • 10.6.1 List Of Key Distributors And Channel Partners
    • 10.6.2 Key Company Market Share Analysis, 2022
  • 10.7 Public Companies
    • 10.7.1 Company Market Position Analysis
    • 10.7.2 Competitive Dashboard Analysis
  • 10.8 Private Companies
    • 10.8.1 List Of Key Emerging Companies
    • 10.8.2 Regional Network Map
    • 10.8.3 Company Market Position Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 CMO Investments in API Biologics - Cell, Gene, Vaccine, and Virus, April - July 2020
  • Table 3 FDA approved Cellular and Gene Therapy Products as of July 2020
  • Table 4 Cell and Gene Therapy Products approved in the European Union
  • Table 5 Summary of risk factors associated with COVID-19 transmission in cell and gene therapy manufacturing
  • Table 6 Impact Analysis
  • Table 7 List of cell therapy manufacturers:
  • Table 8 List of potential end-users
  • Table 9 List of emerging players
  • Table 10 List of market differentiators
  • Table 11 Competitive dashboard analysis
  • Table 12 Regional network map
  • Table 13 Top cell therapy companies of 2022
  • Table 14 Testing methods
  • Table 15 Best Practices for the effective control of raw material
  • Table 16 Operating CMOs/ CDMOs for cell and gene therapy manufacturing in the North America
  • Table 17 Cell and Gene Therapy Manufacturing Capacity in North America as of 2018
  • Table 18 Operating CMOs/ CDMOs for cell and gene therapy manufacturing in the EU
  • Table 19 Cell & Gene Therapy Manufacturing Capacities in Europe 2017
  • Table 20 Distribution of cleanroom footprint, and QC footprint across the U.K.
  • Table 21 Aggregated total number of cellular therapy product manufacturing facilities, GMP laboratories, manufacturing and quality staff, parallel processes and projects by country and state/region.
  • Table 22 Noteworthy regenerative medicine CMOs in operation in Japan
  • Table 23 North America cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 24 North America cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 25 North America cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 26 North America cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 27 North America cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 28 U.S. cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 29 U.S. cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 30 U.S. cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 31 U.S. cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 32 U.S. cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 33 Canada cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 34 Canada cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 35 Canada cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 36 Canada cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 37 Canada cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 38 Europe cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 39 Europe cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 40 Europe cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 41 Europe cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 42 Europe cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 43 Germany cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 44 Germany cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 45 Germany cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 46 Germany cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 47 Germany cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 48 U.K. cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 49 U.K. cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 50 U.K. cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 51 U.K. cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 52 U.K. cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 53 Italy cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 54 Italy cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 55 Italy cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 56 Italy cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 57 Italy cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 58 France cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 59 France cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 60 France cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 61 France cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 62 France cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 63 Spain cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 64 Spain cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 65 Spain cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 66 Spain cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 67 Spain cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 68 Denmark cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 69 Denmark cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 70 Denmark cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 71 Denmark cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 72 Denmark cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 73 Sweden cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 74 Sweden cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 75 Sweden cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 76 Sweden cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 77 Sweden cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 78 Norway cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 79 Norway cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 80 Norway cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 81 Norway cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 82 Norway cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 83 Asia Pacific cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 84 Asia Pacific cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 85 Asia Pacific cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 86 Asia Pacific cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 87 Asia Pacific cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 88 Japan cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 89 Japan cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 90 Japan cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 91 Japan cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 92 Japan cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 93 China cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 94 China cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 95 China cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 96 China cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 97 China cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 98 India cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 99 India cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 100 India cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 101 India cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 102 India cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 103 South Korea cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 104 South Korea cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 105 South Korea cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 106 South Korea cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 107 South Korea cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 108 Thailand cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 109 Thailand cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 110 Thailand cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 111 Thailand cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 112 Thailand cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 113 Australia cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 114 Australia cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 115 Australia cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 116 Australia cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 117 Australia cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 118 Latin America cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 119 Latin America cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 120 Latin America cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 121 Latin America cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 122 Latin America cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 123 Brazil cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 124 Brazil cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 125 Brazil cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 126 Brazil cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 127 Brazil cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 128 Mexico cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 129 Mexico cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 130 Mexico cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 131 Mexico cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 132 Mexico cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 133 Argentina cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 134 Argentina cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 135 Argentina cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 136 Argentina cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 137 Argentina cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 138 MEA cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 139 MEA cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 140 MEA cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 141 MEA cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 142 MEA cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 143 South Africa cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 144 South Africa cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 145 South Africa cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 146 South Africa cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 147 South Africa cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 148 Saudi Arabia cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 149 Saudi Arabia cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 150 Saudi Arabia cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 151. Saudi Arabia cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 152 Saudi Arabia cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 153 UAE cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 154 UAE cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 155 UAE cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 156 UAE cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 157 UAE cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 158 Kuwait cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 159 Kuwait cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 160 Kuwait cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 161 Kuwait cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 162 Kuwait cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Medicines in development, by disease
  • Fig. 9 Classification of companies
  • Fig. 10 Cell and gene therapy manufacturing market snapshot, 2022 (USD Million)
  • Fig. 11 Cell & gene therapy manufacturing market segmentation
  • Fig. 12 Market dynamics
  • Fig. 13 Market driver relevance analysis (Current & future impact)
  • Fig. 14 Most common therapeutic areas targeted by cell therapies in development
  • Fig. 15 Gene therapy clinical trials number as of 2021
  • Fig. 16 Regenerative medicine clinical trials
  • Fig. 17 Expedited approval pathway designations by technology
  • Fig. 18 Market restraint relevance analysis (Current & future impact)
  • Fig. 19 Cell and gene therapy market SWOT analysis
  • Fig. 20 Cell and gene therapy market Porter's five forces analysis
  • Fig. 21 Cell therapy manufacturing collaborations from 2014 to 2018
  • Fig. 22 Areas of disruption due to COVID-19 reported by respondents
  • Fig. 23 Global financings for Cell and Gene therapy. (USD Billion)
  • Fig. 24 UK cell and gene therapy manufacturing capacity, 2016 to 2019
  • Fig. 25 Number of gene therapy sites across gene therapy and multifunctional facilities in the UK, 2019
  • Fig. 26 Breakdown of CoGs per process for cell therapy manufacture
  • Fig. 27 Comparison of costs estimated by campaign, day rate, and hybrid models
  • Fig. 28 Campaign model for cell and gene therapies production
  • Fig. 29 Day rate model for cell and gene production
  • Fig. 30 Hybrid model for cell and gene therapies production
  • Fig. 31 The proportion of funds allocation in anti-EBV CTLs and PSCs
  • Fig. 32 Impact Analysis
  • Fig. 33 Cell and gene therapy market: Therapy type outlook and key takeaways
  • Fig. 34 Cell and gene therapy market: therapy type movement analysis
  • Fig. 35 Cell therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 36 Cell therapy manufacturing market estimates and forecast for stem cell therapy, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 37 Cell therapy manufacturing market estimates and forecast for non-stem cell therapy, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 38 Gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 39 Cell and gene therapy manufacturing market: Scale outlook and key takeaways
  • Fig. 40 Cell and gene therapy manufacturing market: Scale movement analysis
  • Fig. 41 Number of cell therapy clinical trials, by phase, 2020
  • Fig. 42 Number of CAR-T cell therapy clinical trials, by phase, as of September 2019
  • Fig. 43 Cell and gene therapy manufacturing market estimates and forecast for precommercial-scale manufacturing, 2018 - 2030 (USD Million)
  • Fig. 44 Cell and gene therapy manufacturing market estimates and forecast for commercial-scale manufacturing, 2018 - 2030 (USD Million)
  • Fig. 45 Cell and gene therapy manufacturing market: Mode outlook and key takeaways
  • Fig. 46 Cell and gene therapy manufacturing market: Mode movement analysis
  • Fig. 47 Cell and gene therapy manufacturing market for contract manufacturing, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 48 Cell and gene therapy manufacturing market for in-house manufacturing, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 49 Cell and gene therapy manufacturing market: Workflow outlook and key takeaways
  • Fig. 50 Cell and gene therapy manufacturing market: Workflow outlook and key takeaways
  • Fig. 51 Cell and gene therapy manufacturing market: Workflow movement analysis
  • Fig. 52 Cell and gene therapy manufacturing market for cell processing, 2018 - 2030 (USD Million)
  • Fig. 53 Cell and gene therapy manufacturing market for cell banking, 2018 - 2030 (USD Million)
  • Fig. 54 Cell and gene therapy manufacturing market for process development, 2018 - 2030 (USD Million)
  • Fig. 55 Cell and gene therapy manufacturing market for fill and finish operations, 2018 - 2030 (USD Million)
  • Fig. 56 Cell and gene therapy manufacturing market for analytical and quality testing, 2018 - 2030 (USD Million)
  • Fig. 57 Cell and gene therapy manufacturing market for raw material testing, 2018 - 2030 (USD Million)
  • Fig. 58 Gene therapy manufacturing facilities: Trends & types
  • Fig. 59 Gene therapy clinical trials
  • Fig. 60 Viral vectors used in clinical trials
  • Fig. 61 Cell and gene therapy manufacturing market for vector production, 2018 - 2030 (USD Million)
  • Fig. 62 Cell and gene therapy manufacturing market for others, 2018 - 2030 (USD Million)
  • Fig. 63 Cell and gene therapy manufacturing market: Regional outlook and key takeaways
  • Fig. 64 Cell and gene therapy manufacturing market: Regional movement analysis
  • Fig. 65 North America cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Canada cell and gene therapy manufacturing) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Europe cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Germany cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 U.K. cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 France cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Italy cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Spain cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Denmark cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Sweden cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Norway cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Asia Pacific cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Japan cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 China cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 India cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 South Korea cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Australia cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Thailand cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Brazil cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Mexico cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 Argentina cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East & Africa cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 UAE cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 93 Strategy framework
  • Fig. 94 Market participation categorization